Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
May 17, 2022
Assignees:
Massachusetts Institute of Technology, The Broad Institute, Inc.
Inventors:
Chengcheng Jin, Georgia Lagoudas, Paul Blainey, Tyler Jacks
Abstract: There is provided a fusion construct of formula (I): X-A-linker-B-Z (I) wherein: (1) A and B are identical or different and are independently: (a) a polypeptide comprising a SACOL0029 polypeptide as set forth in any one of the sequences depicted in FIG. 24 (SEQ ID NOs: 5 and 121 to 131), a SACOL0264 polypeptide (SEQ ID NO: 185), a SACOL0442 polypeptide as set forth in any one of the sequences depicted in FIG. 22D (SEQ ID NOs: 29 and 82 to 92), a SACOL0718 polypeptide (SEQ ID NO: 186), a SACOL0720 polypeptide as set forth in any one of the sequences depicted in FIGS. 23I-J (SEQ ID NOs: 11 and 109 to 120), a SACOL1353 polypeptide (SEQ ID NO: 187), a SACOL1416 polypeptide (SEQ ID NO: 188), a SACOL1611 polypeptide (SEQ ID NO: 189), a SACOL1867 polypeptide as set forth in any one of the sequences depicted in FIG.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
May 10, 2022
Assignee:
SOCPRA—SCIENCES ET GENIE, s.e.c.
Inventors:
François Malouin, Céline Ster, Julie Côté-Gravel, Éric Brouillette
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
October 19, 2021
Date of Patent:
May 10, 2022
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The present invention is directed to a composition of Lactobacillus fermentum for use in the treatment of a fructose-related disease and a related method of treatment.
Abstract: The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.
Type:
Grant
Filed:
August 14, 2020
Date of Patent:
April 12, 2022
Assignee:
Yale University
Inventors:
Richard Flavell, Noah Palm, Marcel de Zoete
Abstract: The present invention discloses modified Staphylococcus aureus HIa proteins which show reduced tendency to aggregate, improving protein stability and yield. Said modified HIa proteins optionally also contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified HIa protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked to an amino acid residue of the modified HIa protein.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
March 29, 2022
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Martin Braun, Amirreza Faridmoayer, Sabina Marietta Gerber, Markus Mueller
Abstract: Engineered bacteria that secrete therapeutic polypeptides, pharmaceutical compositions comprising the bacteria, methods for producing recombinant polypeptides, and methods for using the bacteria for diagnostic and therapeutic purposes are provided.
Type:
Grant
Filed:
August 31, 2017
Date of Patent:
March 22, 2022
Assignee:
President and Fellows of Harvard College
Abstract: Methods and apparatus for rapid, culture and/or label free pathogen detection. The methods utilize optical spectroscopy techniques to identify and/or characterize pathogens in a sample via the detection of unique properties and/or analytes that are specific to particular pathogens.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
March 15, 2022
Assignee:
STC.UNM
Inventors:
Aaron Kurt Neumann, Anatoliy O Pinchuk, Ke Jiang
Abstract: The invention provides methods of treating disease, such as hypercholesterolemia (e.g., by modulating serum lipids, such as cholesterol, low-density lipoproteins, high-density lipoproteins, and triglycerides) and hyperglycemia by administering Bacillus Calmette-Guerin (BCG). Methods of the invention also encompass the use of genomic, proteomic, and metabolomic analyses for determining the likelihood that a patient has disease or will respond to treatment (e.g., with BCG therapy), as well as for determining whether a patient previously administered BCG would benefit from BCG redosing.
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
March 8, 2022
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
Abstract: Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
March 1, 2022
Assignees:
Ramot at Tel-Aviv University Ltd., The Universitv Court of the University of Glasgow
Inventors:
Oded Rechavi, Shahar Bracha, Lilach Sheiner
Abstract: The present disclosure provides immunogenic materials and methods useful for reducing the risk of fungal infections, particularly valley fever. The disclosure also provides assays for identifying compounds useful to treat valley fever, as well as methods for ameliorating the symptoms of valley fever.
Type:
Grant
Filed:
August 31, 2020
Date of Patent:
March 1, 2022
Assignee:
Arizona Board of Regents on Behalf of the University of Arizona
Inventors:
Marc J. Orbach, Lisa F. Shubitz, Hema P. Narra
Abstract: Provided herein are Haemophilus influenzae saccharide-carrier conjugates and compositions thereof. Also provided are methods of making and using the conjugates and compositions thereof, and kits containing the conjugates. Haemophilus influenzae saccharide-lipid conjugates, Haemophilus influenzae saccharide-glycosphingolipid conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed. Saccharide-lipid conjugates, and saccharide-glycosphingolipid conjugates comprising saccharides from Haemophilus influenzae serotype a, as well as compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed.
Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
Type:
Grant
Filed:
November 2, 2018
Date of Patent:
February 8, 2022
Assignee:
Glaxosmithkline Biologicals S.A.
Inventors:
Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Abstract: A method of producing drug resistant cells including contacting exosomes from a living organism exhibiting drug resistance with cells exhibiting no drug resistance such that drug resistant cells are formed, and culturing the drug resistant cells.
Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
January 11, 2022
Assignee:
SANOFI PASTEUR BIOLOGICS, LLC
Inventors:
Stephen F. Anderson, Natalie Anosova, Nicola Beltraminelli, Pierre Garrone, Harold Kleanthous, Jianxin Zhang, Majid Mehtali
Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
Type:
Grant
Filed:
September 1, 2020
Date of Patent:
January 4, 2022
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Educat
Inventors:
Andrea Gambotto, Louis Falo, Jr., Eun Kim
Abstract: A telodendrimer-nanolipoprotein particle (t-NLP), comprising one or more membrane forming lipids, one or more telodendrimers, and a scaffold protein and a Chlamydia major outer membrane protein (MOMP) comprising a MOMP hydrophobic region, and related compositions methods and systems.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
December 28, 2021
Assignee:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Inventors:
Matthew A. Coleman, Nicholas O. Fischer, Amy Rasley, Craig D. Blanchette, Todd Peterson
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
June 7, 2021
Date of Patent:
December 21, 2021
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad